Navigation Links
PDL BioPharma Announces Record Date for October 1 Dividend Payment
Date:6/10/2009

INCLINE VILLAGE, Nev., June 10 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that all shareholders owning shares of PDL on September 17, 2009, will be paid a dividend of $0.50 per share on October 1, 2009. The Company previously announced that it would pay two dividends, each in the amount of $0.50 per share, to its stockholders in 2009. The first dividend was paid on April 1, 2009 to all stockholders who owned shares of PDL on March 16, 2009.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
2. SAFE-BioPharma Webinar Featuring ARX's Digital Signatures Combined with Microsoft SharePoint for Bio-Pharma industry
3. Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award
4. The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate
5. SAFE-BioPharma Webinar Featuring ARX's Digital Signature Solution and Adobe LiveCycle Combined Solution
6. Sinobiopharma Announces 350% Increase in Production of Its Flagship Drug in the First Quarter of 2009 Over the Same Period in 2008
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
8. PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer
9. Sinobiopharma, Inc. Signs Sales Contract for Flagship Project
10. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
11. Maryland Business, Academic and Biopharma Groups Underscore Commitment to Medical Innovation, Finding Cures for Cancer and Other Diseases and Supporting the Economy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi and ... who do not do their research and undergo cosmetic dermatology treatments from unqualified practitioners ... of a renaissance and every other month a new treatment or device is launched, ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... called the CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial ... healthcare settings. , Over the last 60 years, studies have shown that ...
(Date:12/4/2016)... ... 03, 2016 , ... While James Earl Jones is known for myriad roles ... show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a very ... in large part due to early detection. Like any other disease, treatments have a ...
(Date:12/4/2016)... CA (PRWEB) , ... December 04, 2016 , ... ... without undergoing major cosmetic surgery can now take advantage of a cosmetic procedure ... advanced skin rejuvenation treatment that reduces the appearance of age spots, fine ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in ... Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New ... Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... innovative, personalized cell-based treatment for a high-risk form of the most common ... Hospital of Philadelphia today reported new results using ... The physician-scientists presented findings at the annual meeting of the American ... Continue Reading ... ...
(Date:12/2/2016)... , Dec 2, 2016 Research and Markets ... newsletter to their offering. ... , , R&D Drug ... Publishing,s proprietary R&D Drug Pipeline Database provides 24/7 online access to ... on the market and on investigational drug candidates in research & ...
(Date:12/2/2016)... Columbia , December 2, 2016 - bioLytical lanza el ... nuevas directrices de la OMS     Continue Reading ... ... , , ... enfermedades infecciosas, ha anunciado hoy que está expandiendo el lanzamiento de su INSTI ...
Breaking Medicine Technology: